Compare ASTRAZENECA PHARMA with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DISHMAN PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DISHMAN PHARMA ASTRAZENECA PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 76.3 25.1 304.3% View Chart
P/BV x 21.5 3.3 642.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
ASTRAZENECA PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278374 341.3%   
Low Rs883129 684.7%   
Sales per share (Unadj.) Rs228.4197.8 115.5%  
Earnings per share (Unadj.) Rs10.421.2 48.9%  
Cash flow per share (Unadj.) Rs16.334.7 46.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs98.8179.9 54.9%  
Shares outstanding (eoy) m25.0080.69 31.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.3 371.8%   
Avg P/E ratio x104.211.9 878.4%  
P/CF ratio (eoy) x66.47.2 916.7%  
Price / Book Value ratio x10.91.4 781.9%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m27,00820,306 133.0%   
No. of employees `0001.40.8 163.6%   
Total wages/salary Rs m1,5355,355 28.7%   
Avg. sales/employee Rs Th4,210.919,252.7 21.9%   
Avg. wages/employee Rs Th1,132.26,459.5 17.5%   
Avg. net profit/employee Rs Th191.12,064.1 9.3%   
INCOME DATA
Net Sales Rs m5,71015,961 35.8%  
Other income Rs m123265 46.2%   
Total revenues Rs m5,83316,226 35.9%   
Gross profit Rs m4634,103 11.3%  
Depreciation Rs m1471,091 13.5%   
Interest Rs m0944 0.0%   
Profit before tax Rs m4382,334 18.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179624 28.7%   
Profit after tax Rs m2591,711 15.1%  
Gross profit margin %8.125.7 31.5%  
Effective tax rate %40.826.7 152.8%   
Net profit margin %4.510.7 42.3%  
BALANCE SHEET DATA
Current assets Rs m3,20911,018 29.1%   
Current liabilities Rs m2,0709,517 21.7%   
Net working cap to sales %20.09.4 212.3%  
Current ratio x1.61.2 133.9%  
Inventory Days Days72110 65.5%  
Debtors Days Days3535 100.2%  
Net fixed assets Rs m79016,304 4.8%   
Share capital Rs m50161 31.0%   
"Free" reserves Rs m2,41912,907 18.7%   
Net worth Rs m2,46914,516 17.0%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m4,60529,805 15.5%  
Interest coverage xNM3.5-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.5 231.5%   
Return on assets %5.68.9 63.1%  
Return on equity %10.511.8 89.0%  
Return on capital %17.717.5 101.2%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m3004,952 6.0%   
Fx outflow Rs m2,015697 289.2%   
Net fx Rs m-1,7154,255 -40.3%   
CASH FLOW
From Operations Rs m882,786 3.2%  
From Investments Rs m-94-1,529 6.1%  
From Financial Activity Rs mNA-941 0.0%  
Net Cashflow Rs m-6316 -1.8%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.7 8.1%  
FIIs % 15.7 12.7 123.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 22.1 41.2%  
Shareholders   12,856 46,261 27.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 16, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS